Tonix recently reported results from second positive Phase 3 trial of Tonmya™ for the management of fibromyalgia In the U.S., New Drug Application (NDA) submission to the FDA planned for the second half of 2024 In Japan, China and most countries in Europe cyclobenzaprine is a New Chemical Entity CHATHAM, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of developme
Related Keywords
Japan , Spain , Barcelona , Comunidad Autonoma De Cataluna , China , Zembrace Symtouch , Ben Shannon , Seth Lederman , Jessica Morris , Peter Vozzo , Drug Administration , Bio Europe Spring Convention , Exchange Commission , Tonix Pharmaceuticals Holding Corp , Nasdaq , Tonix Pharmaceuticals , New Drug Application , New Chemical , Pharmaceuticals Holding , Chief Executive Officer , Europe Spring Convention , One Partnering , Breakthrough Therapy , Private Securities Litigation Reform Act , Annual Report , Iopharmaceutical Company , Fibromyalgia Symptoms , Product Development , Product Candidates , Fibromyalgia , Primary Endpoint , Development Portfolio , Development , Clinical Development ,
comparemela.com © 2020. All Rights Reserved.